Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.
Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor, and it has been shown to improve progression-free survival in patients with recurrent glioblastome multiforme when administered as second-line therapy. However, it has been associated with serious and fatal hemorrhagic events. Here, we present a 68-year-old male who developed severe periocular bleeding while on bevacizumab for recurrent temozolamide-resistant glioblastome multiforme.
1 Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Melek K
MK
Eryılmaz
1 Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Hasan
H
Mutlu
1 Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Fatma
F
Yalçin Müsri
1 Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Derya K
DK
Salim
2 Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey.
Gökhan
G
Tazegül
1 Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Hasan Ş
HŞ
Coşkun
D000368:Aged; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D000068258:Bevacizumab / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D005123:Eye; D017809:Fatal Outcome; D005909:Glioblastoma / Q000188:drug therapy*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab
Bevacizumab; bleeding; recurrent glioblastome multiforme